Figure 5. SP5-2-LD enhances survival in a metastatic tumor animal model.
C57BL/6 mice were injected i.v. with 1×105 LL/2 cells, incubated for 24 hours, and then treated with different doxorubicin formulations via i.v. injections twice a week. Mice were treated with either 1 mg/kg or 2 mg/kg of SP5-2-LD, MP5-2-LD, LD, FD or PBS (n = 8). The survival rate is shown in (A, C) for 1 and 2 mg/kg treatment, respectively. Body weight is shown in (B, D) for 1 and 2 mg/kg treatment, respectively. (**, p value <0.01; ***, p value <0.005.)